[Killing of leukemic cells by anti-CD3McAb plus rIL-2 activated cord blood].
OBJECTIVE
To investigate the killing efficacy of cord blood monocyte activated by Anti-CD3 monoclonal antibody(McAb) in K562 and HL-60 cell lines.


METHODS
By using indirect rosette forming test, antigen expression rate of monocyte was detected. The levels of interleukin-8 (IL-8), IL-6 and tumor necrosis factor alpha (TNF-alpha) were measured by ELISA. The killing efficacy in 3H-thymidine target cells was detected by beta-liquid scintillator.


RESULTS
After being activated by Anti-CD3McAb and rIL-2, the antigen expression of monocyte was changed markedly. The levels of IL-8, IL-6 and TNF-alpha were increased; The Anti-CD3 McAb activated killer cells produced significant lysis in K562 and HL-60 cell lines and the optimum conditions were as follows: concentration of cells, 1 x 10(6)/ml; Anti-CD3McAb, 1 microgram/ml; rIL-2 1,000 U/ml; time of culture, 72 hrs; ratio of effector/target: 100:1.


CONCLUSIONS
Anti-CD3 McAb activated killer cells exhibited a strong cytotoxicity to leukemic cells. Our study provides a theoretical basis for the adoptive immunotherapy of leukemia by activated cord blood.
Jin
Y
Y
Department of Pediatrics, Second Hospital, Hubei Medical University, Wuhan 430077.
Zhang
Y
Y
Zou
D
D
D000911:Antibodies, Monoclonal / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D005312:Fetal Blood / Q000166:cytology*; D018922:HL-60 Cells / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology*; D020014:K562 Cells / Q000276:immunology; D016260:Monocytes, Activated Killer / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology
D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007376:Interleukin-2; D011994:Recombinant Proteins